Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Emapalumab-Izsg
DRUG
2 trials
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
, Hellenic Institute for the Study of Sepsis
Conditions
Chronic Granulomatous Disease
Sepsis
Phase 1
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting
NCT05463133
National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
Start: 2022-07-08
End: 2032-12-31
Target: 50
Updated: 2026-05-14
Phase 2
Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)
Active, not recruiting
NCT06694701
Hellenic Institute for the Study of Sepsis
Sepsis
Start: 2025-03-22
End: 2026-11-30
Target: 75
Updated: 2025-11-19